ESR1 and breast cancer: This finding has allowed us to identify several Food and Drug Administration (FDA)-approved drugs, initially designed for different purposes, which possess ‘anti-estrogen-like’ properties, inducing ERα degradation and effectively halting the proliferation of BC cell lines9–17.